Opioid Use Disorder
📧 Sign up to get email alerts when something new happens for Opioid Use Disorder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2019-08-22Clinical Trial Update: Clinical Trial of CAM2038, Long-acting Subcutaneous Buprenorphine Injections for Treatment of Patients With Opioid Dependence [Phase 3]
Phase 3 trial update for CAM2038, a long-acting subcutaneous buprenorphine injection, in opioid use disorders has completed with results pos…
-
FDA approval · 2019-08-22FDA Approved: METHADONE HYDROCHLORIDE — Original Application (SpecGx LLC)
FDA approved a generic methadone hydrochloride product (SpecGx LLC) under an Original Application.
-
CLINICAL_TRIALS trial_result · 2019-08-01Clinical Trial Update: Long-Term Safety Study of Buprenorphine (CAM2038) in Adult Outpatients With Opioid Use Disorder [Phase 3]
Long-term safety study results for CAM2038 (buprenorphine) in adults with opioid use disorder have been completed.
-
CLINICAL_TRIALS trial_result · 2019-07-10Clinical Trial Update: Utility of Olanzapine in the Treatment of Opioid Withdrawal in the ED [NA]
Clinical trial assessing olanzapine for opioid withdrawal in the emergency department has completed, with results posted in 2019.
-
FDA approval · 2019-06-07FDA Approved: VIVITROL — Supplemental Application (Alkermes, Inc.)
The FDA approved a supplemental application for VIVITROL (naltrexone) submitted by Alkermes, Inc.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2019-05-03Clinical Trial Update: Interim Buprenorphine Treatment to Bridge Waitlist Delays: Stage II Evaluation [Phase 2]
-
EMA approval · 2019-04-26New long-lasting implant to treat opioid dependence
The EMA reports a new long-acting implant for the treatment of opioid dependence, expanding available options for managing opioid use disord…
-
CLINICAL_TRIALS trial_result · 2019-02-26Clinical Trial Update: Comparing Treatments for HIV-Infected Opioid and Alcohol Users in an Integrated Care Effectiveness Study [Phase 3]
A Phase 3 trial comparing treatments for opioid use disorder and alcohol use disorder in HIV-infected individuals has completed with results…
-
CLINICAL_TRIALS trial_result · 2019-02-12Clinical Trial Update: Evaluating Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Transitioning From Buprenorphine Maintenance Prior to First Dose of VIVITROL [Phase 3]
A Phase 3 trial evaluated the use of naltrexone in combination with buprenorphine for adults with opioid use disorder transitioning from bup…
-
CLINICAL_TRIALS trial_result · 2019-02-12Clinical Trial Update: Negating Opioid and Pain Actively Through Intervention [NA]
A completed clinical trial from Loma Linda University investigating an intervention to reduce opioid use and manage chronic pain.
-
CLINICAL_TRIALS trial_result · 2019-02-01Clinical Trial Update: Behavioral Activation for Heroin Use in China: A Randomized Controlled Trial [NA]
A randomized controlled trial conducted in China evaluated Behavioral Activation for heroin use in individuals with opioid use disorder and …
-
CLINICAL_TRIALS trial_result · 2019-01-29Clinical Trial Update: Pupil Response in Patients on Opioids.
Oslo University Hospital completed a clinical trial evaluating pupil response in patients on opioids. The study encompassed individuals with…
-
FDA approval · 2019-01-24FDA Approved: BUPRENORPHINE AND NALOXONE SUBLINGUAL FILM — Original Application (Alvogen Inc.)
FDA approved a generic buprenorphine and naloxone sublingual film (Original Application) for the treatment of opioid dependence, with Alvoge…
-
CLINICAL_TRIALS trial_result · 2019-01-23Clinical Trial Update: Combining Opioid Addiction Treatment Services With CARe for Infectious Endocarditis [NA]
A completed clinical trial evaluating integrating opioid addiction treatment with CARe for infective endocarditis.
-
CLINICAL_TRIALS trial_result · 2019-01-09Clinical Trial Update: Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to First Dose of VIVITROL® (Naltrexone for Extended-Release Injectable Suspension) [Phase 3]
Phase 3 trial evaluating naltrexone initiation in adults with opioid use disorder before the first dose of VIVITROL extended-release naltrex…
-
FDA approval · 2019-01-03FDA Approved: METHADONE HYDROCHLORIDE — Original Application (Camber Pharmaceuticals, Inc)
FDA approved Camber Pharmaceuticals' Methadone Hydrochloride Original Application (ANDA 211228).
-
FDA approval · 2018-12-28FDA Approved: VIVITROL — Supplemental Application (Alkermes, Inc.)
FDA approved a supplemental application for VIVITROL (naltrexone) from Alkermes, Inc., authorizing changes to the product's labeling under a…
-
FDA approval · 2018-11-20FDA Approved: BUPRENORPHINE — Original Application (Teva Pharmaceuticals USA, Inc.)
FDA approved Teva Pharmaceuticals USA, Inc.'s original application for generic buprenorphine, enabling its marketing in the United States fo…
-
CLINICAL_TRIALS trial_result · 2018-11-02Clinical Trial Update: Open-Label Treatment Extension Study [Phase 3]
An open-label treatment extension study (Phase 3) for opioid use disorder and related disorders has completed with results posted.
-
FDA approval · 2018-10-31FDA Approved: BUPRENORPHINE HCL AND NALOXONE HCL — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA granted a supplemental approval to Amneal Pharmaceuticals for Buprenorphine HCl and Naloxone HCl, expanding the product's approved formu…
-
FDA approval · 2018-10-31FDA Approved: ZUBSOLV — Supplemental Application (Orexo US, Inc.)
FDA approved a supplemental application for ZUBSOLV, the buprenorphine/naloxone sublingual product from Orexo US, Inc.
-
FDA approval · 2018-10-31FDA Approved: BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
The FDA approved a supplemental NDA for buprenorphine hydrochloride and naloxone hydrochloride dihydrate manufactured by Hikma Pharmaceutica…
-
FDA approval · 2018-10-31FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approves a supplemental application for Sun Pharmaceutical's buprenorphine/naloxone product, updating its regulatory status for treating…
-
FDA approval · 2018-10-31FDA Approved: BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE — Supplemental Application (SpecGx LLC)
The FDA approved SpecGx LLC's supplemental application for a buprenorphine hydrochloride and naloxone hydrochloride dihydrate product, a gen…
-
FDA approval · 2018-10-31FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approves a supplemental application for buprenorphine and naloxone from Mylan Pharmaceuticals, signaling an update to the product's appr…